April 17, 2014

Akorn on Thursday announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal for $640 million in cash.

April 17, 2014

Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.

April 17, 2014

Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals.

April 17, 2014

Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

April 16, 2014

Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.

April 15, 2014

Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

April 15, 2014

Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.

April 15, 2014

Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form.

April 15, 2014

Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

April 15, 2014

Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States.

April 11, 2014

Now available online, the Drug Enforcement Administration National Prescription Drug Take-Back Day collection site locator allows consumers to search for a nearby location to dispose of unneeded medications on Saturday, April 26, 2014, the National Association of Boards of Pharmacy announced Wednesday.

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

April 11, 2014

NCPDP, the not-for-profit pharmacy standards development organization, on Wednesday announced the availability of a patient safety white paper that provides specific industry guidance for standardizing the dosing designations and labeling of oral liquid medications.

April 11, 2014

Ian Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America at the trade association’s annual meeting.

April 10, 2014

Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths.

April 9, 2014

According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children.

April 8, 2014

Healthcare Distribution Management Association president and CEO John Gray on Monday testified before the House Energy and Commerce Subcommittee on Health at a hearing on “Improving Predictability and Transparency in DEA and FDA Regulation.”

April 8, 2014

Ohio Gov. John Kasich got his first look on Tuesday at what’s being called a next-generation pharmaceutical distribution center — under construction in central Ohio.

April 8, 2014

Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

April 7, 2014

Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion.

April 4, 2014

IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders.